BOSTON--(BUSINESS WIRE)--Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D. and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases..

波士顿--（商业新闻短讯）--Cure Ventures（“Cure”）是一家生命科学风险投资公司，专注于围绕开创性的治疗技术组建公司，今天宣布任命行业领袖杰夫·乔纳斯（Jeff Jonas，M.D.）和阿尔·罗比绍德（Al-Robichaud，Ph.D.）为合作伙伴，以扩大该公司与生物技术企业家在开发治疗改变生命的疾病的疗法方面的合作。。

For more than 30 years, Dr. Jonas has thrived in R&D leadership and cutting-edge drug discovery, both of which are at the heart of Cure’s mission. Most recently he was the chief executive officer (CEO) of the incubation platform, ABio-X. He was previously the CEO of Sage Therapeutics, where he developed several advances in central nervous system treatments.

30多年来，乔纳斯博士在研发领导和尖端药物发现方面取得了巨大成就，这两者都是Cure使命的核心。最近，他担任孵化平台ABio-X的首席执行官（CEO）。他之前是Sage Therapeutics的首席执行官，在那里他在中枢神经系统治疗方面取得了一些进展。

Millions of people across the globe may have been potentially helped by drugs where Dr. Jonas has led organizations and teams responsible for the development and support of medicines such as Mirapex, Lexapro, Vyvanse, Zulresso, Zurzuvae and Namenda..

Jonas博士领导的组织和团队负责药物的开发和支持，如Mirapex，Lexapro，Vyvanse，Zulresso，Zurzuvae和Namenda，全球数百万人可能已经获得了药物的潜在帮助。。

“Much of my career has been spent finding medicines that can make a meaningful difference in the lives of patients, and that aligns very well with Cure’s goals,” said Dr. Jonas. “I’m excited to join this stellar leadership team. I’ve known the partners for many years. It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.

乔纳斯博士说：“我职业生涯的大部分时间都花在寻找可以对患者生活产生重大影响的药物上，这与治愈的目标非常吻合。”。“我很高兴加入这个一流的领导团队。我认识这些合作伙伴很多年了。很明显，Cure有能力战略性地选择合作伙伴并提升他们的工作水平。

The team’s transparency and flexibility are second-to-none as they collaborate with companies and innovators to create new solutions in various disease categories. I can’t wait to get started.”.

该团队的透明度和灵活性首屈一指，因为他们与公司和创新者合作，为各种疾病类别创造新的解决方案。我等不及要开始了。”。

Dr. Jonas has a long history of accelerating growth as evidenced by Sage’s $3 billion alliance with Biogen. A graduate of Harvard Medical School, he has also served as president of Shire Regenerative Medicine, executive vice president of Ionis Pharmaceuticals and chief medical officer of Forest Laboratories..

Jonas博士在加速增长方面有着悠久的历史，Sage与Biogen的30亿美元联盟就是明证。作为哈佛医学院的毕业生，他还曾担任夏尔再生医学院院长、Ionis制药公司执行副总裁和森林实验室首席医疗官。。

“Jeff has an incredible background in advancing companies in their drug development pipeline. More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures. “Bringing Jeff aboard was one of the easiest decisions we’ve made because we know he is capable of taking this firm to the next level.”.

Cure Ventures联合创始人兼管理合伙人戴夫·法拉斯（DaveFallace）表示：“杰夫（Jeff）在推动公司药物开发方面拥有令人难以置信的背景。更重要的是，他是我们行业中最受尊重的领导者。”。“让杰夫加入是我们做出的最简单的决定之一，因为我们知道他有能力将公司提升到一个新的水平。”。

Cure has also added Al Robichaud, Ph.D., former Chief Scientific Officer at Sage, to solidify its leadership team as the firm prepares for new ventures in 2024 and beyond. A Ph.D. recipient in organic chemistry from UC Irvine, Robichaud brings more than 35 years of experience. While at Sage, Robichaud helped launch the company into the public market, and oversaw the discovery and development of two commercially approved drugs, Zulresso and Zurzuvae.

Cure还增加了Sage前首席科学官Al Robichaud博士，以巩固其领导团队，因为该公司正在为2024年及以后的新企业做准备。Robichaud是加州大学欧文分校有机化学博士，拥有35年以上的经验。在Sage任职期间，Robichaud帮助该公司进入公共市场，并监督了两种商业批准药物Zulresso和Zurzuvae的发现和开发。

He also is the primary discovery scientist, and principal inventor of Caplyta, an approved drug for the treatment of bipolar depression. Prior to Sage, Robichaud held multiple leadership roles at large pharmaceutical companies focused primarily on neuroscience..

他也是主要发现科学家，也是Caplyta的主要发明者，Caplyta是一种被批准用于治疗双相抑郁症的药物。在Sage之前，Robichaud在主要专注于神经科学的大型制药公司担任多项领导职务。。

“As Cure looks to its immediate and long-term future, we want to make sure we have a strong leadership team to guide the firm,” said Lou Tartaglia, Ph.D., co-founder and managing partner at Cure Ventures. “Jeff and Al are exactly what we need, when we need it. Their leadership qualities, drug discovery and development expertise, and neuroscience background ensure that Cure not only meets its lofty goals but exceeds them in the advancements of patient care.”.

Cure Ventures联合创始人兼管理合伙人Lou Tartaglia博士表示：“随着Cure展望其眼前和长远的未来，我们希望确保拥有一支强大的领导团队来指导公司。”。“杰夫和艾尔正是我们需要的人。他们的领导才能、药物发现和开发专业知识以及神经科学背景确保治愈不仅能实现其崇高目标，而且在患者护理方面的进步也超过了他们。”。

“I look forward to this next chapter in my career, with the privilege of rejoining my longtime colleague Jeff as well as with the wonderful team at Cure,” added Al Robichaud on his appointment. “The strides science has made in recent years cannot go unnoticed. Cure Ventures is committed to backing this innovation by building companies that seek to make impactful new medicines for patients.”.

Al-Robichaud在任命时补充道：“我期待着我职业生涯的下一个篇章，有幸重新加入我的老同事杰夫以及Cure的出色团队。”。“近年来科学取得的进步不可忽视。Cure Ventures致力于通过建立公司来支持这项创新，这些公司寻求为患者生产有影响力的新药。”。

Cure was founded by a network of highly accomplished industry veterans, including Managing Partners, Richard (Rich) Lim, M.B.A.; David (Dave) Fallace, J.D., M.B.A.; and Lou Tartaglia, Ph.D. The managing partners have played major roles in the success of several biotechnology companies, including Juno Therapeutics, Agios Therapeutics, Nuvation Bio and many others..

Cure由一批成就卓著的行业资深人士组成，其中包括管理合伙人Richard（Rich）Lim，M.B.a。；大卫（戴夫）法拉斯，J.D.，M.B.A。；和Lou Tartaglia博士。管理合伙人在几家生物技术公司的成功中发挥了重要作用，包括Juno Therapeutics，Agios Therapeutics，Nuvation Bio和许多其他公司。。

About Cure Ventures

关于Cure Ventures

Founded in 2021, Cure Ventures is a life sciences venture capital firm focusing on de novo company formation around groundbreaking curative technologies. Above all else, the Cure team leads with respect for people and for science. Led by highly accomplished industry veterans, Cure’s investment thesis is founded on three tenets: A seed funding model that allows Cure to de-risk the science and set companies up for success; genetic validation that increases the probability of success; and embedded Cure operators to drive the best day-to-day decision making in collaboration with founders.

Cure Ventures成立于2021年，是一家生命科学风险投资公司，专注于围绕开创性的治疗技术从头组建公司。最重要的是，Cure团队在尊重人类和科学方面处于领先地位。在成就卓著的行业老手的带领下，Cure的投资论文基于三个宗旨：种子基金模式，使Cure能够降低科学风险并建立成功的公司；增加成功概率的基因验证；和嵌入式Cure运营商，与创始人合作，推动最佳的日常决策。

For more information, please visit: www.curevc.com.

有关更多信息，请访问：www.curevc.com。